Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin N Heller

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of Experimental Medicine|March 22, 2006
Virus-specific CD4+ T cells: ready for direct attackKevin N Heller, Cagan Gurer, Christian Münz
Blood|September 21, 2006
Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriersKevin N Heller, Jenica Upshaw, Beza Seyoum, et al.
Journal of Pediatric Hematology/Oncology|February 10, 2004
Primary follicular lymphoma of the testis: excellent outcome following surgical resection without adjuvant chemotherapyKevin N Heller, Julie Teruya-Feldstein, Michael P La Quaglia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Case Report: response to ipilimumab in a patient with HIV with metastatic melanomaMatthew M Burke, Harriet M Kluger, Marjorie Golden, et al.
International Journal of Cancer|September 11, 2008
Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1Kevin N Heller, Frida Arrey, Peter Steinherz, et al.
Journal of Clinical Pharmacology|October 28, 2011
Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjectsBlisse Vakkalagadda, Jong-Soon Park, Christoph M Ahlers, et al.
International Journal of Cancer|December 18, 2008
Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responsesAnn M Moormann, Kevin N Heller, Kiprotich Chelimo, et al.
European Thyroid Journal|November 16, 2016
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid CancerLars Bastholt, Michael C Kreissl, Dagmar Führer, et al.
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Experimental Medicine|March 22, 2006
Virus-specific CD4+ T cells: ready for direct attackKevin N Heller, Cagan Gurer, Christian Münz
Blood|September 21, 2006
Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriersKevin N Heller, Jenica Upshaw, Beza Seyoum, et al.
Journal of Pediatric Hematology/Oncology|February 10, 2004
Primary follicular lymphoma of the testis: excellent outcome following surgical resection without adjuvant chemotherapyKevin N Heller, Julie Teruya-Feldstein, Michael P La Quaglia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Case Report: response to ipilimumab in a patient with HIV with metastatic melanomaMatthew M Burke, Harriet M Kluger, Marjorie Golden, et al.
International Journal of Cancer|September 11, 2008
Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1Kevin N Heller, Frida Arrey, Peter Steinherz, et al.
Journal of Clinical Pharmacology|October 28, 2011
Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjectsBlisse Vakkalagadda, Jong-Soon Park, Christoph M Ahlers, et al.
International Journal of Cancer|December 18, 2008
Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responsesAnn M Moormann, Kevin N Heller, Kiprotich Chelimo, et al.
European Thyroid Journal|November 16, 2016
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid CancerLars Bastholt, Michael C Kreissl, Dagmar Führer, et al.
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
Pageof 1